Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis

We evaluated the cost-utility of replacing trivalent influenza vaccine (TIV) with quadrivalent influenza vaccine (QIV) in the current target populations in Uruguay. An existing decision-analytic static cost-effectiveness model was adapted for Uruguay. The population was stratified into age groups. C...

Full description

Bibliographic Details
Main Authors: Pablo Manuel Bianculli, Lucile Bellier, Ignacio Olivera Mangado, Carlos Grau Pérez, Gustavo Mieres, Luis Lazarov, Audrey Petitjean, Hugo Dibarboure, Juan Guillermo Lopez
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
uruguay
cost-effectiveness
influenza
vaccine switch
trivalent vaccine
quadrivalent vaccine
public health impact
Online Access:http://dx.doi.org/10.1080/21645515.2022.2050653

Internet

http://dx.doi.org/10.1080/21645515.2022.2050653

Similar Items